ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
62.14
-0.20 (-0.32%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close62.34
Open62.21
Bid0.00 x 4000
Ask0.00 x 1800
Day's Range62.04 - 62.49
52 Week Range47.83 - 64.60
Volume5,121,291
Avg. Volume5,746,685
Market Cap108.943B
Beta1.68
PE Ratio (TTM)232.73
EPS (TTM)0.27
Earnings DateJul 18, 2018
Forward Dividend & Yield1.12 (1.78%)
Ex-Dividend Date2018-07-12
1y Target Est68.40
Trade prices are not sourced from all markets
  • Cramer continues review of $100 billion club with 2018's ...
    CNBC Videos7 days ago

    Cramer continues review of $100 billion club with 2018's ...

    Jim Cramer surveys the 15 newest companies to reach $100 billion market caps and points out the best investments in the group.

  • Wall Street Analysts Are Mostly Positive on Celgene in June
    Market Realist11 hours ago

    Wall Street Analysts Are Mostly Positive on Celgene in June

    Celgene (CELG) reported revenues of $3.5 billion in Q1 2018, which reflected ~20% year-over-year (or YoY) growth and 1% growth sequentially. In Q1 2018, Celgene’s adjusted diluted EPS (earnings per share) rose ~23% YoY to reach $2.05. In Q1 2018, Celgene reported a gross product margin and an operating margin of 96.4% and 57.9%, respectively.

  • Abbott Hosts Conference Call for Second-Quarter Earnings
    PR Newswire16 hours ago

    Abbott Hosts Conference Call for Second-Quarter Earnings

    ABBOTT PARK, Ill., June 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018 , before the market opens.  The announcement will ...

  • Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
    Zacks3 days ago

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

  • How Much Upside Do Analysts See for Stryker?
    Market Realist5 days ago

    How Much Upside Do Analysts See for Stryker?

    In this series, we’ll analyze what analysts think about the company, how its product lines have performed, and how its first-quarter financials look. Of the 27 analysts covering Stryker in June, 18 analysts have given the stock a “buy” or higher rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.0 with a target price of $181.36, implying upside potential of 7.5% over the stock’s closing price of $168.75 on June 14.

  • Should You Be Concerned With Abbott Laboratories’s (NYSE:ABT) -73.52% Earnings Drop?
    Simply Wall St.6 days ago

    Should You Be Concerned With Abbott Laboratories’s (NYSE:ABT) -73.52% Earnings Drop?

    When Abbott Laboratories (NYSE:ABT) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happening inRead More...

  • Allergan appoints former Abbott executive to its board
    Reuters7 days ago

    Allergan appoints former Abbott executive to its board

    Allergan, whose director Patrick O'Sullivan will retire from the board in July, said its board will continue to have 12 members of which 10 are independent, following the changes. Freyman, who retired from Abbott in 2017, most recently served as executive vice president, finance and administration for the company since June 2015.

  • GlobeNewswire7 days ago

    Report: Developing Opportunities within Abbott Laboratories, Markel, Microsoft, Gazit-Globe, National General, and ANGI Homeservices — Future Expectations, Projections Moving into 2018

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abbott ...

  • DexCom Stock History
    Motley Fool7 days ago

    DexCom Stock History

    Here's how this small medical device company is helping to tackle diabetes and why it might be worth buying in your portfolio.

  • CNBC7 days ago

    Cramer introduces the market's newest high-quality stock group: The $100 billion club

    "Mad Money" host Jim Cramer surveys the 15 newest companies to reach $100 billion market caps and points out the best investments in the group. Over the years, CNBC's Jim Cramer has found that in a bull market, the winners tend to keep winning. The only way a company gets its name on this list is by producing years and years of gains," Cramer said.

  • 10 Dividend Aristocrats You Never Have to Worry About
    InvestorPlace8 days ago

    10 Dividend Aristocrats You Never Have to Worry About

    The fact of the matter is, however, for many investors the bulk of their total investing profits reaped for the long haul will come from dividends… even dividends that are reinvested in the companies paying them. With that as the backdrop, here’s a rundown of the market’s highest-quality dividend stocks … dividend payers that could be considered the aristocrats among the market’s income-oriented investments.

  • Abbott Declares 378th Consecutive Quarterly Dividend
    PR Newswire13 days ago

    Abbott Declares 378th Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 378th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2018, to shareholders of record at the close of business on July 13, 2018.

  • Bio-Rad Banks on Solid Global Scenario, Competition Rife
    Zacks13 days ago

    Bio-Rad Banks on Solid Global Scenario, Competition Rife

    Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.

  • The brain stimulator communicator: Tears of joy are just a happy byproduct in manager’s line of work
    American City Business Journals14 days ago

    The brain stimulator communicator: Tears of joy are just a happy byproduct in manager’s line of work

    Abbott Laboratories' Lisa Distenfield is tasked with communicating the intricacies of the latest groundbreaking neuro technology.

  • CNBC15 days ago

    For investors looking for a summer fling, one sector could fit the bill

    Health care has been the best-performing sector between June and August since 1990, according to a new Oppenheimer note. But if the sector rallied this year, not all names in the group will participate, says the firm’s top technician.

  • Guardian Connect Expected to Be Medtronic’s Big Opportunity
    Market Realist16 days ago

    Guardian Connect Expected to Be Medtronic’s Big Opportunity

    On March 12, Medtronic announced that it has received FDA approval for its stand-alone CGM (continuous glucose monitoring) system Guardian Connect. The system is the first smart stand-alone CGM system that allows patients to proactively manage their glucose levels. Medtronic expects to launch the device in the first quarter of fiscal 2019.

  • Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
    Zacks19 days ago

    Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

    Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

  • Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management
    PR Newswire21 days ago

    Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

    The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit. The Afinion 2 analyzer is a compact rapid, multi-assay platform that streamlines and simplifies the delivery of actionable, accurate measurements of hemoglobin A1c (HbA1c) and albumin to creatinine ratio (ACR) results at the point of care.

  • TheStreet.com22 days ago

    Jim Cramer's List of 88 Stocks to Watch With Interest Rates Falling Again

    U.S. government debt prices caught a nice bid on Tuesday as investors flocked to the relative safety of the U.S. with the European Union coming under fire. While bank stocks stand to lag with rates under pressure (banks tend see higher profit margins when rates rise), there are hosts of equities that could see an upward push. "The stocks that do well in a declining rate environment have come roaring back and the crash of oil will only accelerate the move," says TheStreet's founder Jim Cramer in an extensive column for Real Money, our premium site for active traders and Wall Street professionals.

  • How Incyte’s Jakafi Performed in Q1 2018
    Market Realist22 days ago

    How Incyte’s Jakafi Performed in Q1 2018

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

  • TheStreet.com22 days ago

    Medical Device Stocks Could Be Gearing Up to Be Market Leaders

    Medical devices is another industry that Jim Cramer believes will hold up better in this current environment of volatile energy prices and interest rates. Let's take a look at five companies in this space, Baxter International Inc. The chart and indicators of Baxter International show underlying strength and could outperform the averages in the days and weeks ahead.

  • InvestorPlace23 days ago

    The 7 Best Long-Term Stocks for Risk-Off Investors

    “While the parameters of what defines a long-term-focused company are still somewhat squishy, the limited evidence so far suggests that they make better investments too,” wrote Fortune’s Clifton Leaf. S&P Dow Jones Indices’ October 2017 report, Long-Termism: Index Impossible?, looked at the S&P Long-Term Value Creation (LTVC) Global Index, an index created to hold mid- and large-size companies that embody long-termism, which is the idea of making decisions based on a sustainable future-oriented perspective. If it’s got anything to do with water there’s a good chance that Xylem Inc (NYSE:XYL) is involved in some capacity.

  • The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
    Zacks23 days ago

    The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

    The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman